Every 10-Q that ReposiTrak, Inc. (TRAK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TRAK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAK filings page.
ReposiTrak, Inc. reported stable results for the quarter ended March 31, 2026, with revenue of $5.9 million, down 1% year over year, and quarterly net income of $2.0 million. Higher-margin recurring subscription revenue and lower expenses lifted income from operations to $2.3 million.
For the nine months, revenue rose 5% to $17.7 million and net income reached $5.5 million, while diluted EPS increased to $0.28. The company ended the period with cash of $26.4 million, positive working capital of $26.3 million, and no bank debt.
ReposiTrak continued capital returns, including common share repurchases and ongoing redemption of its Series B preferred stock, leaving $1.72 million of preferred value outstanding. The board also declared a quarterly dividend of $0.02 per share. The company entered a new $3.0 million unsecured note receivable at an 8% rate with potential equity-linked return features.
ReposiTrak, Inc. reported higher sales and profits for the quarter and six months ended December 31, 2025 while maintaining a strong cash position and returning capital to shareholders.
Quarterly revenue rose to $5.86 million from $5.49 million, driven mainly by recurring subscription and support services across compliance, supply chain and traceability. Net income applicable to common shareholders increased to $1.64 million, with diluted earnings per share of $0.09, up from $0.08 a year earlier, helped by lower cost of services and reduced depreciation and amortization.
For the first half of fiscal 2026, revenue reached $11.83 million and net income applicable to common shareholders was $3.40 million, both above the prior-year period. The company ended the quarter with $28.7 million in cash and cash equivalents and no bank debt, and generated $3.78 million in operating cash flow over six months.
ReposiTrak continued redeeming its Series B preferred stock and repurchased common shares under its long-running buyback program, while also paying cash dividends. A quarterly dividend of $0.02 per share was declared in December 2025. Management highlights growing demand for its traceability platform as the food industry prepares for U.S. FDA FSMA 204 traceability requirements, with the compliance deadline now extended to July 20, 2028.
ReposiTrak, Inc. (TRAK) reported Q1 FY2026 results. Revenue was $5,971,467, up 10% year over year, driven by recurring subscription and support services of $5,941,467. Net income was $1,819,529, and diluted EPS was $0.09. Income from operations reached $1,893,873.
Cash and cash equivalents were $28,794,806, with deferred revenue of $2,686,197 and no bank debt. Operating cash flow was $1,538,447. The company redeemed 70,093 shares of Series B Preferred for $749,995 and repurchased 8,715 common shares for $149,985. A quarterly cash dividend of $0.02 per share was declared. As of November 13, 2025, 18,288,455 common shares were outstanding.
Management highlights growth across compliance, supply chain, and traceability offerings as industry mandates expand. Total stockholders’ equity increased to $50,169,744.